Executive Summary: For AI companies, data is often the primary source of durable value. Proprietary training datasets, data network effects, and exclusive data agreements can create defensible advantages that reduce customer churn, improve model performance, and support premium valuation multiples. For Houston business owners, investors, and advisors, understanding how these data moats translate into higher […]
Generative AI startup valuation is driven less by a single formula and more by a disciplined read of recurring revenue quality, contract economics, defensibility, and margin profile. For Houston business owners, investors, and advisors, the central question is not whether a GenAI company is growing, but whether that growth is durable enough to command a […]
Executive Summary: Valuing an artificial intelligence company requires more than applying a standard revenue multiple or discounted cash flow model. Investors and buyers evaluate recurring revenue quality, model differentiation, data advantages, compute economics, customer retention, and the scalability of gross margins. For Houston business owners, especially those in technology, healthcare, energy, and adjacent professional services, […]
Executive Summary: Electronic health record (EHR) and health IT software companies are valued less on current earnings alone and more on recurring revenue quality, customer retention, implementation depth, and the cost and complexity of switching systems. For Houston business owners in this sector, the key valuation drivers are annual recurring revenue (ARR), net revenue retention […]
Executive Summary: AI-powered diagnostics companies are valued differently from traditional healthcare businesses because their economics are driven not only by current revenue, but also by FDA clearance, clinical validation, reimbursement readiness, and the durability of licensing relationships. For Houston business owners, investors, and advisors, understanding how diagnostics companies are priced is essential when preparing for […]
Executive Summary: Revenue cycle management (RCM) software businesses are valued on more than just reported revenue. Buyers and investors focus on the strength of recurring revenue, revenue per provider, claim success rates, net revenue retention (NRR), and the degree to which the platform is embedded in a customer’s day-to-day workflow. Because RCM systems sit at […]
Executive summary: Valuing a telehealth platform requires more than looking at headline revenue growth. Buyers and investors pay close attention to patient visit volume, revenue per visit, payer contract penetration, retention, and how the business performs as demand normalizes after the pandemic era. In practice, telehealth platforms are often valued using a blend of discounted […]
Digital health companies are valued differently from traditional service businesses because their worth is tied not only to current earnings, but also to recurring revenue quality, patient engagement, clinical credibility, and regulatory readiness. For Houston business owners, investors, and advisors, understanding how healthtech companies are priced is essential when preparing for a sale, raising capital, […]
Executive Summary: InsurTech valuations depend on more than topline growth. Buyers and investors look closely at loss ratio, combined ratio, premium growth, retention, and the quality of distribution to determine whether growth is durable and profitable. In a sector where technology can accelerate customer acquisition and underwriting efficiency, valuation still comes down to disciplined financial […]
Executive Summary: Buy-now-pay-later, or BNPL, was once valued primarily on growth, user adoption, and gross merchandise volume. That approach has changed. Today, investors and buyers are looking much more closely at the economics behind the volume, including GMV, merchant fee rate, default rate, contribution margin, funding costs, and the path to sustainable profitability. For BNPL […]
- 1
- 2